Use of RNA-Protein Complexes for Genome Editing in Non- albicans Candida Species
- PMID: 28657070
- PMCID: PMC5480035
- DOI: 10.1128/mSphere.00218-17
Use of RNA-Protein Complexes for Genome Editing in Non- albicans Candida Species
Abstract
Clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 genome modification systems have greatly facilitated the genetic analysis of fungal pathogens. In CRISPR-Cas9 genome editing methods designed for use in Candida albicans, DNAs that encode the necessary components are expressed in the target cells. Unfortunately, expression constructs that work efficiently in C. albicans are not necessarily expressed well in other pathogenic species within the genus Candida or the related genus Clavispora. To circumvent the need for species-specific expression constructs, we implemented an expression-free CRISPR genome editing system and demonstrated its successful use in three different non-albicans Candida species: Candida (Clavispora) lusitaniae, Candida glabrata, and Candida auris. In CRISPR-Cas9-mediated genome editing methods, a targeted double-stranded DNA break can be repaired by homologous recombination to a template designed by the investigator. In this protocol, the DNA cleavage is induced upon transformation of purified Cas9 protein in complex with gene-specific and scaffold RNAs, referred to as RNA-protein complexes (RNPs). In all three species, the use of RNPs increased both the number of transformants and the percentage of transformants in which the target gene was successfully replaced with a selectable marker. We constructed mutants defective in known or putative catalase genes in C. lusitaniae, C. glabrata, and C. auris and demonstrated that, in all three species, mutants were more susceptible to hydrogen peroxide than the parental strain. This method, which circumvents the need for expression of CRISPR-Cas9 components, may be broadly useful in the study of diverse Candida species and emergent pathogens for which there are limited genetic tools. IMPORTANCE Existing CRISPR-Cas9 genome modification systems for use in Candida albicans, which rely on constructs to endogenously express the Cas9 protein and guide RNA, do not work efficiently in other Candida species due to inefficient promoter activity. Here, we present an expression-free method that uses RNA-protein complexes and demonstrate its use in three Candida species known for their drug resistance profiles. We propose that this system will aid the genetic analysis of fungi that lack established genetic systems.
Keywords: CRISPR; Candida; auris; genome editing; glabrata; lusitaniae; molecular methods.
Figures




Similar articles
-
Development of a CRISPR-Cas9 System for Efficient Genome Editing of Candida lusitaniae.mSphere. 2017 Jun 21;2(3):e00217-17. doi: 10.1128/mSphere.00217-17. eCollection 2017 May-Jun. mSphere. 2017. PMID: 28657072 Free PMC article.
-
Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.mSphere. 2018 Jun 13;3(3):e00208-18. doi: 10.1128/mSphereDirect.00208-18. Print 2018 Jun 27. mSphere. 2018. PMID: 29898980 Free PMC article.
-
Comparison of genome engineering using the CRISPR-Cas9 system in C. glabrata wild-type and lig4 strains.Fungal Genet Biol. 2017 Oct;107:44-50. doi: 10.1016/j.fgb.2017.08.004. Epub 2017 Aug 16. Fungal Genet Biol. 2017. PMID: 28822858
-
New insights of CRISPR technology in human pathogenic fungi.Future Microbiol. 2019 Sep;14:1243-1255. doi: 10.2217/fmb-2019-0183. Future Microbiol. 2019. PMID: 31625446 Review.
-
CRISPR/Cas9-mediated correction of human genetic disease.Sci China Life Sci. 2017 May;60(5):447-457. doi: 10.1007/s11427-017-9032-4. Epub 2017 May 3. Sci China Life Sci. 2017. PMID: 28534256 Review.
Cited by
-
Functional genetic characterization of stress tolerance and biofilm formation in Nakaseomyces (Candida) glabrata via a novel CRISPR activation system.mSphere. 2024 Feb 28;9(2):e0076123. doi: 10.1128/msphere.00761-23. Epub 2024 Jan 24. mSphere. 2024. PMID: 38265239 Free PMC article.
-
Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata.Emerg Microbes Infect. 2019;8(1):1619-1625. doi: 10.1080/22221751.2019.1684209. Emerg Microbes Infect. 2019. PMID: 31711370 Free PMC article.
-
The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection.PLoS Pathog. 2019 Aug 5;15(8):e1007460. doi: 10.1371/journal.ppat.1007460. eCollection 2019 Aug. PLoS Pathog. 2019. PMID: 31381597 Free PMC article.
-
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species.Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01387-19. doi: 10.1128/AAC.01387-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31611349 Free PMC article.
-
Genetic Modification of Closely Related Candida Species.Front Microbiol. 2019 Mar 19;10:357. doi: 10.3389/fmicb.2019.00357. eCollection 2019. Front Microbiol. 2019. PMID: 30941104 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources